Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.50% -0.02% 113.11M 13100.40
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (Since Inception)
0.20% 81.00% -14.21M Upgrade

Basic Info

Investment Strategy
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Health
Fund Owner Firm Name ALPS
Prospectus Benchmark Index
S-Network Medical Breakthroughs TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Ryan Mischker 8.85 yrs
Andrew Hicks 7.84 yrs

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of February 23, 2024. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Loading chart...
Name
2017
2018
2019
2020
2021
2022
2023
YTD
45.63%
-11.71%
50.30%
21.17%
-17.55%
-28.08%
8.68%
8.13%
22.40%
-8.71%
27.67%
15.90%
21.82%
-18.14%
23.79%
5.36%
22.28%
-0.19%
18.65%
25.66%
1.54%
-10.83%
3.71%
-1.89%
50.15%
-1.23%
34.45%
67.26%
-3.20%
-20.61%
-4.54%
12.88%
30.50%
8.91%
22.31%
32.91%
3.04%
-23.34%
-6.23%
2.77%
43.77%
-15.27%
32.56%
48.33%
-20.45%
-25.87%
7.60%
6.11%
As of February 23, 2024.

Asset Allocation

As of February 23, 2024.
Type % Net % Long % Short
Cash 0.05% Upgrade Upgrade
Stock 99.95% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Basic Info

Investment Strategy
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Health
Fund Owner Firm Name ALPS
Prospectus Benchmark Index
S-Network Medical Breakthroughs TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Ryan Mischker 8.85 yrs
Andrew Hicks 7.84 yrs

Top Portfolio Holders

0 of 0